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Background:  Monitoring of EBV-DNA load is frequently applied for the identiﬁ cation 
of patients at risk for posttransplant lymphoproliferative disease (PTLD). EBV-DNA can 
be measured in different compartments; plasma and whole blood. Which of these 
compartments is preferable to determine EBV-DNA load is still a matter of debate. 
Methods: We compared levels of EBV-DNA in whole blood and plasma using a real 
time TaqMan PCR assay in 100 consecutive paired whole blood and plasma samples 
from 25 lung and heart-lung transplant recipients with detectable whole blood EBV-
DNA load (> 2.000 copies/ml). 
Results: A correlation (r squared) of 0.58 (P < 0.001) was observed between both 
measurements. Of all positive whole blood samples (>2.000 copies/ml), only 17 
samples (18%) were also positive in plasma. 
Conclusions: These results indicate that whole blood, by virtue of its sensitivity, rather 

























Post-transplant lymphoproliferative disease (PTLD) encompasses a heterogeneous 
group of diseases, ranging from Epstein-Barr virus (EBV) driven polyclonal proliferation 
resembling infectious mononucleosis to monomorphic proliferations which may 
be indistinguishable from aggressive types of lymphoma such as diffuse large 
B-cell lymphoma. Generally, PTLD is considered an iatrogenic complication of 
immunosuppression after transplantation, leading to a decrease in EBV speciﬁ c T-
cells, which, in turn, may lead to uncontrolled proliferation of EBV infected B-cells. 
Incidence varies signiﬁ cantly between different types of organ transplants, with 
the highest incidences (5-20%) found after lung and small bowel transplantation. 
Monitoring of Epstein-Barr virus (EBV)-DNA load in transplant recipients by quantitative 
PCR (qPCR) is frequently applied for the identiﬁ cation of patients at risk for PTLD1-3. 
Over the last years, attention has been focused on these PCR-based approaches for 
early (i.e., prior to clinical presentation) diagnosis of PTLD. In addition, pre-emptive 
reduction of immunosuppression based on EBV-DNA load has been shown to lead to 
a decrease in PTLD incidence in paediatric liver transplant recipients4. 
EBV-DNA can be measured in plasma, peripheral blood mononuclear cells 
(PBMCs) and whole blood. It has already been shown that there is a strong correlation 
between the EBV-DNA load measured in whole blood by TaqMan PCR and in 
PBMCs by competitive (c)PCR, indicating that the former method appears to be 
an acceptable alternative to the latter5. This is important, because qPCR is less time 
consuming than cPCR, thereby allowing a more rapid clinical decision based on EBV-
DNA load measurements. The correlation between EBV-DNA load as measured in 
plasma or whole blood is not clear yet. Both methods are frequently applied and no 
consensus has been reached which compartment is preferable to determine EBV-
DNA load6-8. A study by Wadowsky et al. showed a correlation of 0.71 between both 
measurements in 59 tested samples from 44 paediatric transplant recipients9. One 
could argue that there is an underestimation of EBV-DNA load in plasma as whole 
blood contains all EBV-DNA (i.e., cell free and cell associated), whereas plasma 
contains only cell free virus. 
As data are far from conclusive, our aim was to compare the capacity of both 
measurements to detect EBV-DNA. 
METHODS
Samples
Between January 2004 and May 2005, we prospectively collected all plasma 
samples from lung and heart-lung transplant recipients with detectable whole blood 
EBV-DNA loads (> 2000 copies/ml). A total of one hundred consecutive plasma samples 
(stored at −80°C until testing) from 25 lung and heart-lung transplant recipients was 
collected and available for testing. Six plasma samples were excluded from analysis 
because of haemolysis. 
78 
DNA puriﬁ cation and PCR assay
The BioRobot EZ1 Robotic workstation was used for automated DNA puriﬁ cation 
(The EZ1 Virus Card for plasma, the EZ1 DNA Blood Card for whole blood). DNA was 
extracted from 200-μl portions of plasma and whole blood, and eluted in 100μl and 
200μl of buffer AE, respectively.
For the TaqMan PCR assay a primer-probe set for EBNA-1 was used; the nucleotide 
sequences (5′→3′) were as follows: upstream primer, CCGGTGTGTTCGTATATGG; 
downstream primer, AAAGGGGAGACGACTCAATG; and minor groove binding 
(MGB) probe, CTATTCCACAATGTCGTCTTA, designed with Primer express software 
version 1.5 (PE Biosystems, Nieuwerkerk aan de IJssel, The Netherlands). For the PCR, 
the ABI prism 7900 HT-RealTime-PCR system (384 wells) was used. Samples of 10 μl 
plasma and whole blood were used as input in the PCR, while 10 μl of exogenous 
internal positive control mix (Applied Biosystems, California, US ) was used as a 
template to identify possible inhibition of the PCR. The concentration of EBV-DNA 
was determined from a reference standard quantiﬁ ed by electron microscopy (ABI 
Advanced Biotechnologies Incorporated, Columbia, US). The viral load in plasma as 
well as in whole blood was expressed as the number of copies per millilitre. Each 
sample was tested in fourfold and EBV DNA load was expressed as the mean of these 
four samples. 
The lower detection limit of our assay was a cycle threshold of around 35, which 
corresponds to 2.000 copies/ml in whole blood and, because of a concentration 
step, 1.000 copies/ml in plasma. Plasma EBV-DNA load levels below this lower limit 




Patient characteristics and results of EBV-DNA load measurements are 
shown in table 1. Median number of EBV-DNA load measurements in the 25 lung 
transplant patients was 4 (range 1-8). Five patients were EBV seronegative prior to 
transplantation. 
Of all positive samples in whole blood, only 17 samples (18 %) were detectable 
when measured in plasma. Of the ﬁ rst positive samples in whole blood obtained from 
these 25 patients, only 4 (16 %) samples were detected in plasma. These positive 
samples measured in plasma included the two highest EBV-DNA load values measured 
in whole blood (patient 7&11).
Correlation between plasma and whole blood levels 
None of the samples inhibited the ampliﬁ cation of the internal positive control in 
the TaqMan PCR assay. When analysing all samples together, a correlation of 0.58 (p 
< 0.001) was observed (ﬁ gure 1).  When comparing the correlation between values 
positive in whole blood as well as in plasma (>1000 copies/ml), a correlation of 0.49 (p 




































































































































































































































































































































































































































































































































Figure 1 Correlation of EBV-DNA load in plasma and whole blood samples (n=94 pairs) measured 
by TaqMan PCR. Plasma EBV-DNA load levels below the lower limit of detection (1000 copies/ml) 
were coded as 1.000 copies/ml.
Figure 2 Correlation of EBV-DNA load in plasma and whole blood of all samples tested positive in 
whole blood as well as in plasma (n=17). 
DISCUSSION 
This study aimed to compare EBV-DNA load measured in whole blood with that 
in plasma. Only 17% percent of all positive samples in whole blood were detectable 























than reported by Wadowsky et al.9. Taken into account the lower detection limit 
of our assay (>1000 copies/ml and > 2000 copies/ml in plasma and whole blood, 
respectively) we can, however, not exclude that with the use of a more sensitive 
detection assay (e.g. reliable detection of >50 copies/ml) more plasma samples 
would have been positive. 
The current literature does not identify which type of specimen is superior for 
EBV-DNA load monitoring. Some publications suggest the potential utility of plasma 
specimens to identify the patient at risk for PTLD6;10-12. Our results, however, suggest 
that it may be advantageous to monitor EBV-DNA load in whole blood rather than in 
plasma as in the large majority of all samples tested, EBV-DNA load was below cut-off 
value in plasma. 
During the period in which we collected whole blood and plasma samples we 
intervened (tapering of immunosuppression) when patients had two consecutive 
specimens with elevated EBV-DNA loads with the last measurement exceeding 10.000 
copies/ml as measured in whole blood. As this policy led to only one patient (#25) 
ultimately developing PTLD, it is not possible to assess the positive predictive value of 
plasma and whole blood samples for the development of PTLD. However, our results 
indicate that if plasma had been used as the leading specimen for decision making, 
many patients would have been withholding clinical intervention, which is tapering of 
immunosuppression. This approach seems useful, because we previously showed that 
whole blood EBV-DNA load in these lung transplant recipients can be used to both 
predict and diagnose PTLD, and strongly correlates with changes in the immune status 
of the patient1.  Our observations further indicate that the elevated EBV-DNA load in 
these patients can be attributed mainly to the cellular compartment of the blood, 
directly reﬂ ecting proliferation of latently infected B cells, with little or no lytic viral 
replication and associated release of virion DNA. This conﬁ rms the results of Stevens et 
al, who already speculated on the poor diagnostic and predictive values of tests with 
serum and plasma samples as clinical specimens for the development of PTLD7.  
There is a limitation to this study relating to the selection of the samples; only 
samples with positive EBV-DNA load as measured in whole blood were included. 
Hypothetically, samples negative in whole blood could be positive in plasma. However, 
given the results of our study, this seems very unlikely as 95% of all positive plasma 
samples had lower EBV-DNA loads than measured in whole blood. This indicates that 
even when EBV-DNA load is detectable in plasma, a large discrepancy with respect 
to quantitative values is present when comparing measurements in whole blood and 
plasma, indicating that the large majority of all EBV-DNA is still cell-bound during EBV 
reactivation. 
Given our results and the considerations mentioned above, we conclude that 
whole blood rather than plasma is the preferable specimen for the detection of EBV-
DNA in lung transplant recipients.
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